NO311760B1 - Eprosartandihydrat, anvendelse og fremgangsmåte for fremstilling derav, og farmasöytisk preparat inneholdende dette - Google Patents

Eprosartandihydrat, anvendelse og fremgangsmåte for fremstilling derav, og farmasöytisk preparat inneholdende dette Download PDF

Info

Publication number: NO311760B1
Authority: NO; Norway
Prior art keywords: compound; pharmaceutical preparation; compound according; butyl; preparation
Prior art date: 1996-03-29

Application number

NO19984503A

Other languages

English (en)

Norwegian (no)

Other versions

NO984503L (no

NO984503D0 (no

Inventor

Nageswara R Palepu

Gopadi M Venkatesh

Sarma Duddu

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-29

Filing date

1998-09-28

Publication date

2002-01-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO311760(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-09-28 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

1998-09-28 Publication of NO984503L publication Critical patent/NO984503L/no

1998-09-28 Publication of NO984503D0 publication Critical patent/NO984503D0/no

2002-01-21 Publication of NO311760B1 publication Critical patent/NO311760B1/no

Links

238000002360 preparation method Methods 0.000 title claims description 24
-1 Eprosartan dihydrate Chemical class 0.000 title claims description 18
238000000034 method Methods 0.000 title claims description 15
239000002080 C09CA02 - Eprosartan Substances 0.000 title description 15
229960004563 eprosartan Drugs 0.000 title description 15
239000008194 pharmaceutical composition Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 46
239000000654 additive Substances 0.000 claims description 22
239000008187 granular material Substances 0.000 claims description 22
239000000825 pharmaceutical preparation Substances 0.000 claims description 22
150000004683 dihydrates Chemical class 0.000 claims description 16
HIUNDVRJXJGSGV-KMDBKMSFSA-N 4-[[2-butyl-5-[(e)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid;methanesulfonic acid;dihydrate Chemical group O.O.CS(O)(=O)=O.C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 HIUNDVRJXJGSGV-KMDBKMSFSA-N 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
229940079593 drug Drugs 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 11
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
206010020772 Hypertension Diseases 0.000 claims description 10
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 10
239000007909 solid dosage form Substances 0.000 claims description 10
239000002934 diuretic Substances 0.000 claims description 8
238000002156 mixing Methods 0.000 claims description 8
230000001882 diuretic effect Effects 0.000 claims description 7
238000005469 granulation Methods 0.000 claims description 7
230000003179 granulation Effects 0.000 claims description 7
239000002461 renin inhibitor Substances 0.000 claims description 7
229940086526 renin-inhibitors Drugs 0.000 claims description 7
229940127291 Calcium channel antagonist Drugs 0.000 claims description 6
239000011230 binding agent Substances 0.000 claims description 6
239000000480 calcium channel blocker Substances 0.000 claims description 6
239000002775 capsule Substances 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 6
239000002532 enzyme inhibitor Substances 0.000 claims description 6
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical group C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 6
238000001953 recrystallisation Methods 0.000 claims description 6
206010007559 Cardiac failure congestive Diseases 0.000 claims description 5
206010019280 Heart failures Diseases 0.000 claims description 5
208000001647 Renal Insufficiency Diseases 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 5
230000000996 additive effect Effects 0.000 claims description 5
239000007864 aqueous solution Substances 0.000 claims description 5
230000000903 blocking effect Effects 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
238000001035 drying Methods 0.000 claims description 5
229940125532 enzyme inhibitor Drugs 0.000 claims description 5
239000000945 filler Substances 0.000 claims description 5
201000006370 kidney failure Diseases 0.000 claims description 5
229940098779 methanesulfonic acid Drugs 0.000 claims description 5
102000008873 Angiotensin II receptor Human genes 0.000 claims description 4
108050000824 Angiotensin II receptor Proteins 0.000 claims description 4
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 4
229960002003 hydrochlorothiazide Drugs 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
108010061435 Enalapril Proteins 0.000 claims description 3
229960000830 captopril Drugs 0.000 claims description 3
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
229960000873 enalapril Drugs 0.000 claims description 3
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 3
238000011049 filling Methods 0.000 claims description 3
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 3
229960003883 furosemide Drugs 0.000 claims description 3
239000002171 loop diuretic Substances 0.000 claims description 3
229960001597 nifedipine Drugs 0.000 claims description 3
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical group COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 3
229960003712 propranolol Drugs 0.000 claims description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 2
238000003860 storage Methods 0.000 claims description 2
102000015427 Angiotensins Human genes 0.000 claims 2
108010064733 Angiotensins Proteins 0.000 claims 2
239000005541 ACE inhibitor Substances 0.000 claims 1
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
238000005422 blasting Methods 0.000 claims 1
239000000314 lubricant Substances 0.000 claims 1
DJSLTDBPKHORNY-XMMWENQYSA-N eprosartan methanesulfonate Chemical compound CS(O)(=O)=O.C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 DJSLTDBPKHORNY-XMMWENQYSA-N 0.000 description 17
OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 13
229920002472 Starch Polymers 0.000 description 11
239000008107 starch Substances 0.000 description 11
229940032147 starch Drugs 0.000 description 11
235000019698 starch Nutrition 0.000 description 11
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
239000008101 lactose Substances 0.000 description 9
238000002411 thermogravimetry Methods 0.000 description 8
238000005550 wet granulation Methods 0.000 description 8
229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
239000008186 active pharmaceutical agent Substances 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
229940088679 drug related substance Drugs 0.000 description 5
239000000243 solution Substances 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
230000003111 delayed effect Effects 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229940014259 gelatin Drugs 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
238000000634 powder X-ray diffraction Methods 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 3
239000003929 acidic solution Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
229940069328 povidone Drugs 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
239000000230 xanthan gum Substances 0.000 description 3
235000010493 xanthan gum Nutrition 0.000 description 3
229920001285 xanthan gum Polymers 0.000 description 3
229940082509 xanthan gum Drugs 0.000 description 3
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical class CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
229940049654 glyceryl behenate Drugs 0.000 description 2
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
238000009478 high shear granulation Methods 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000012729 immediate-release (IR) formulation Substances 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000012907 medicinal substance Substances 0.000 description 2
UAAKJEVCDBPTQS-UHFFFAOYSA-N methanesulfonic acid;dihydrate Chemical compound O.O.CS(O)(=O)=O UAAKJEVCDBPTQS-UHFFFAOYSA-N 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
235000010413 sodium alginate Nutrition 0.000 description 2
239000000661 sodium alginate Substances 0.000 description 2
229940005550 sodium alginate Drugs 0.000 description 2
238000001757 thermogravimetry curve Methods 0.000 description 2
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
102000005862 Angiotensin II Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
229940097420 Diuretic Drugs 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000004368 Modified starch Substances 0.000 description 1
229940121792 Thiazide diuretic Drugs 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
229950008138 carmellose Drugs 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000012738 dissolution medium Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000009837 dry grinding Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229940046813 glyceryl palmitostearate Drugs 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
238000010952 in-situ formation Methods 0.000 description 1
230000007574 infarction Effects 0.000 description 1
229910052816 inorganic phosphate Inorganic materials 0.000 description 1
229910052920 inorganic sulfate Inorganic materials 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
AZNLMXLZWYULEU-UHFFFAOYSA-N methanesulfonic acid 3-thiophen-2-ylpropanoic acid Chemical compound CS(O)(=O)=O.OC(=O)CCc1cccs1 AZNLMXLZWYULEU-UHFFFAOYSA-N 0.000 description 1
IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
230000003387 muscular Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
230000009862 primary prevention Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
230000009863 secondary prevention Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000007669 thermal treatment Methods 0.000 description 1
239000003451 thiazide diuretic agent Substances 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
238000001238 wet grinding Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19984503A 1996-03-29 1998-09-28 Eprosartandihydrat, anvendelse og fremgangsmåte for fremstilling derav, og farmasöytisk preparat inneholdende dette NO311760B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1441496P	1996-03-29	1996-03-29
PCT/US1997/004877 WO1997036874A1 (fr)	1996-03-29	1997-03-26	Dihydrate d'eprosartan, procede de fabrication et formulation

Publications (3)

Publication Number	Publication Date
NO984503L NO984503L (no)	1998-09-28
NO984503D0 NO984503D0 (no)	1998-09-28
NO311760B1 true NO311760B1 (no)	2002-01-21

Family

ID=21765344

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO19984503A NO311760B1 (no)	1996-03-29	1998-09-28	Eprosartandihydrat, anvendelse og fremgangsmåte for fremstilling derav, og farmasöytisk preparat inneholdende dette
NO2002005C NO2002005I1 (no)	1996-03-29	2002-07-19	Eprosartan

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2002005C NO2002005I1 (no)	1996-03-29	2002-07-19	Eprosartan

Country Status (35)

Country	Link
EP (1)	EP0889880B1 (fr)
JP (1)	JP4316013B2 (fr)
CN (2)	CN1214682A (fr)
AP (1)	AP901A (fr)
AR (1)	AR006439A1 (fr)
AT (1)	ATE239723T1 (fr)
AU (1)	AU726694B2 (fr)
BG (1)	BG64095B1 (fr)
BR (1)	BR9708336A (fr)
CA (1)	CA2250395C (fr)
CZ (1)	CZ293345B6 (fr)
DE (1)	DE69721749T2 (fr)
DK (1)	DK0889880T3 (fr)
DZ (1)	DZ2199A1 (fr)
EA (1)	EA001958B1 (fr)
EG (1)	EG23889A (fr)
ES (1)	ES2198564T3 (fr)
HU (1)	HU228263B1 (fr)
ID (1)	ID16507A (fr)
IL (1)	IL126319A0 (fr)
MA (1)	MA24437A1 (fr)
MY (1)	MY117682A (fr)
NO (2)	NO311760B1 (fr)
NZ (1)	NZ332008A (fr)
OA (1)	OA11176A (fr)
PL (1)	PL188816B1 (fr)
PT (1)	PT889880E (fr)
RO (1)	RO118870B1 (fr)
SK (1)	SK282346B6 (fr)
TR (1)	TR199801954T2 (fr)
TW (1)	TW434239B (fr)
UA (1)	UA49880C2 (fr)
UY (1)	UY24504A1 (fr)
WO (1)	WO1997036874A1 (fr)
ZA (1)	ZA972686B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0991647B1 (fr) *	1997-06-27	2002-09-04	Smithkline Beecham Corporation	Eprosartane monohydrate
US6558699B2 (en) *	1997-11-17	2003-05-06	Smithkline Beecham Corporation	High drug load immediate and modified release oral dosage formulations and processes for their manufacture
PL340587A1 (en) *	1997-11-17	2001-02-12	Smithkline Beecham Corp	Oral preparations of high therapeutic substance content with instantaneous or modifiable release of such substance and methods of obtaining them
ES2214013T3 (es)	1998-03-04	2004-09-01	Takeda Chemical Industries Ltd	Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso.
ZA991922B (en) *	1998-03-11	1999-09-13	Smithkline Beecham Corp	Novel compositions of eprosartan.
AU763309B2 (en) *	1998-07-20	2003-07-17	Smithkline Beecham Corporation	Bioenhanced formulations comprising eprosartan in oral solid dosage form
GB9820405D0 (en) *	1998-09-18	1998-11-11	Smithkline Beecham Plc	Process
WO2000027397A1 (fr) *	1998-11-06	2000-05-18	Glaxo Group Limited	Medicaments antihypertenseurs a base de lacidipine et de telmisartan
WO2000027396A1 (fr) *	1998-11-06	2000-05-18	Glaxo Group Limited	Medicaments a base de combinaisons de lacidipine et de telmisartan ou de derives physiologiques
WO2000066161A1 (fr) *	1999-04-28	2000-11-09	Takeda Chemical Industries, Ltd.	Preventifs / remedes / inhibiteurs de progression pour retinopathie simplex ou retinopathie preproliferante
GB9920917D0 (en)	1999-09-03	1999-11-10	Sb Pharmco Inc	Novel process
GB9920919D0 (en)	1999-09-03	1999-11-10	Sb Pharmco Inc	Novel compound
CA2405793A1 (fr) *	2000-04-12	2001-10-18	Novartis Ag	Combinaison de composes organiques
PL370270A1 (en) *	2001-11-23	2005-05-16	Solvay Pharmaceuticals Gmbh	Hypertonia treatment during the acute phase of a cerebrovascular accident
KR100517638B1 (ko)	2002-04-08	2005-09-28	주식회사 엘지생명과학	게미플록사신 산염의 새로운 제조방법
EG24716A (en)	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
WO2003097099A1 (fr) *	2002-05-17	2003-11-27	Novartis Ag	Combinaison de bloquants du recepteur d'angiotensine ii et de betabloquants pour la prevention secondaire d'infarctus du myocarde
DE10230272A1 (de) *	2002-07-05	2004-01-22	Solvay Pharmaceuticals Gmbh	AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
RS20050590A (sr)	2003-01-31	2007-09-21	Sankyo Company Limited,	Lek za profilaksu i tretman arterioskleroze i hipertenzije
US8361507B2 (en)	2007-07-25	2013-01-29	Hetero Drugs Limited	Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
WO2009084028A2 (fr) *	2007-12-03	2009-07-09	Neuland Laboratories Ltd	Procédé amélioré de fabrication de méthanesulfonate de l'acide (e)-3-[2-butyl-1-{(4-carboxyphényl)méthyl}-1h-imidazol-5-yl]-(thiophén-2-ylméthyl)prop-2-énoïque
CN101333216A (zh) *	2008-08-03	2008-12-31	浙江华海药业股份有限公司	一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) *	2021-06-03	2023-09-15	北京宝诺康医药科技有限公司	一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5312828A (en) *	1989-06-14	1994-05-17	Finkelstein Joseph A	Substituted imidazoles having angiotensin II receptor blocking activity
US5185351A (en) *	1989-06-14	1993-02-09	Smithkline Beecham Corporation	Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
EP0563238B1 (fr) *	1990-12-14	2002-05-22	Smithkline Beecham Corporation	Acides imidazolyl-alcenoiques

1997
- 1997-03-26 AR ARP970101257A patent/AR006439A1/es active IP Right Grant
- 1997-03-26 IL IL12631997A patent/IL126319A0/xx active IP Right Grant
- 1997-03-26 ES ES97917004T patent/ES2198564T3/es not_active Expired - Lifetime
- 1997-03-26 PT PT97917004T patent/PT889880E/pt unknown
- 1997-03-26 CZ CZ19983101A patent/CZ293345B6/cs not_active IP Right Cessation
- 1997-03-26 HU HU9902769A patent/HU228263B1/hu unknown
- 1997-03-26 WO PCT/US1997/004877 patent/WO1997036874A1/fr not_active Ceased
- 1997-03-26 EP EP97917004A patent/EP0889880B1/fr not_active Expired - Lifetime
- 1997-03-26 CN CN97193471A patent/CN1214682A/zh active Pending
- 1997-03-26 AT AT97917004T patent/ATE239723T1/de active
- 1997-03-26 NZ NZ332008A patent/NZ332008A/xx not_active IP Right Cessation
- 1997-03-26 DE DE69721749T patent/DE69721749T2/de not_active Expired - Lifetime
- 1997-03-26 PL PL97329046A patent/PL188816B1/pl unknown
- 1997-03-26 EA EA199800873A patent/EA001958B1/ru not_active IP Right Cessation
- 1997-03-26 BR BR9708336A patent/BR9708336A/pt not_active IP Right Cessation
- 1997-03-26 DK DK97917004T patent/DK0889880T3/da active
- 1997-03-26 UA UA98095006A patent/UA49880C2/uk unknown
- 1997-03-26 AU AU25470/97A patent/AU726694B2/en not_active Expired
- 1997-03-26 RO RO98-01406A patent/RO118870B1/ro unknown
- 1997-03-26 MA MA24539A patent/MA24437A1/fr unknown
- 1997-03-26 JP JP53538497A patent/JP4316013B2/ja not_active Expired - Lifetime
- 1997-03-26 TR TR1998/01954T patent/TR199801954T2/xx unknown
- 1997-03-26 UY UY24504A patent/UY24504A1/es not_active IP Right Cessation
- 1997-03-26 SK SK1322-98A patent/SK282346B6/sk not_active IP Right Cessation
- 1997-03-26 CA CA002250395A patent/CA2250395C/fr not_active Expired - Lifetime
- 1997-03-27 MY MYPI97001335A patent/MY117682A/en unknown
- 1997-03-27 EG EG24497A patent/EG23889A/xx active
- 1997-03-27 AP APAP/P/1997/000956A patent/AP901A/en active
- 1997-03-27 ZA ZA9702686A patent/ZA972686B/xx unknown
- 1997-03-29 DZ DZ970046A patent/DZ2199A1/fr active
- 1997-03-31 ID IDP971059A patent/ID16507A/id unknown
- 1997-06-17 TW TW086108370A patent/TW434239B/zh not_active IP Right Cessation
1998
- 1998-09-28 NO NO19984503A patent/NO311760B1/no not_active IP Right Cessation
- 1998-09-29 OA OA9800184A patent/OA11176A/en unknown
- 1998-10-07 BG BG102822A patent/BG64095B1/bg unknown
2001
- 2001-06-09 CN CN01121133A patent/CN1332167A/zh active Pending
2002
- 2002-07-19 NO NO2002005C patent/NO2002005I1/no unknown

Also Published As

Publication number	Publication date
PL188816B1 (pl)	2005-04-29
AR006439A1 (es)	1999-08-25
DK0889880T3 (da)	2003-09-01
HUP9902769A3 (en)	2000-04-28
CZ293345B6 (cs)	2004-04-14
BG64095B1 (bg)	2003-12-31
SK132298A3 (en)	1999-03-12
HUP9902769A2 (hu)	2000-03-28
IL126319A0 (en)	1999-05-09
DE69721749D1 (de)	2003-06-12
EG23889A (en)	2007-12-12
AU2547097A (en)	1997-10-22
PL329046A1 (en)	1999-03-01
TW434239B (en)	2001-05-16
JP2000508632A (ja)	2000-07-11
NO984503L (no)	1998-09-28
AP901A (en)	2000-11-23
UY24504A1 (es)	1997-09-19
PT889880E (pt)	2003-09-30
SK282346B6 (sk)	2002-01-07
EP0889880A1 (fr)	1999-01-13
HK1016594A1 (en)	1999-11-05
BR9708336A (pt)	1999-08-03
EA199800873A1 (ru)	1999-02-25
OA11176A (en)	2003-05-13
CZ310198A3 (cs)	1999-03-17
HU228263B1 (en)	2013-02-28
DE69721749T2 (de)	2004-03-25
CA2250395C (fr)	2005-09-06
NO2002005I1 (no)	2002-09-02
CN1332167A (zh)	2002-01-23
MA24437A1 (fr)	1998-10-01
WO1997036874A1 (fr)	1997-10-09
BG102822A (en)	1999-11-30
AU726694B2 (en)	2000-11-16
AP9700956A0 (en)	1997-04-30
TR199801954T2 (xx)	1998-12-21
JP4316013B2 (ja)	2009-08-19
UA49880C2 (uk)	2002-10-15
EA001958B1 (ru)	2001-10-22
ZA972686B (en)	1997-09-29
ID16507A (id)	1997-10-02
MY117682A (en)	2004-07-31
CN1214682A (zh)	1999-04-21
ATE239723T1 (de)	2003-05-15
EP0889880B1 (fr)	2003-05-07
ES2198564T3 (es)	2004-02-01
RO118870B1 (ro)	2003-12-30
NO984503D0 (no)	1998-09-28
NZ332008A (en)	1999-05-28
CA2250395A1 (fr)	1997-10-09
DZ2199A1 (fr)	2002-12-03
EP0889880A4 (fr)	1999-06-23

Legal Events

Date	Code	Title	Description
2017-04-03	MK1K	Patent expired

Publication	Publication Date	Title
EP0889880B1 (fr)	2003-05-07	Dihydrate d'eprosartan, procede de fabrication et formulation
AU763309B2 (en)	2003-07-17	Bioenhanced formulations comprising eprosartan in oral solid dosage form
US6558699B2 (en)	2003-05-06	High drug load immediate and modified release oral dosage formulations and processes for their manufacture
CZ303145B6 (cs)	2012-05-02	Zpusob výroby dvojvrstevné farmaceutické tablety obsahující telmisartan a hydrochlorthiazid
US20020137943A1 (en)	2002-09-26	Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
US6420412B2 (en)	2002-07-16	Eprosartan dihydate and a process for its production and formulation
EP1033974B1 (fr)	2014-01-22	Formes posologiques orales a forte dose medicamenteuse et a liberation immediate et modifiee et leurs procedes de fabrication
WO1999025338A1 (fr)	1999-05-27	Compositions pharmaceutiques contenant du zafirlukast
NO317771B1 (no)	2004-12-13	Eprosartanarginyl-ladning-noytraliseringskompleks og en fremgangsmate for dets fremstilling og anvendelse derav
CA2642414C (fr)	2014-08-26	Composition pharmaceutique contenant de l'irbesartan a liberation rapide
KR100477295B1 (ko)	2005-09-09	에프로사르탄이수화물,그의제조방법및조성물
HK1016594B (en)	2004-01-09	Eprosartan dihydrate and a process for its production and formulation
KR20090052944A (ko)	2009-05-27	이르베사르탄을 함유하는 제약 조성물
CZ2001227A3 (cs)	2001-07-11	Biologicky zlepšené prostředky obsahující eprosartan v orální pevné dávkové formě
HK1031688B (en)	2007-07-06	Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
CN121731234A (zh)	2026-03-27	一种布瑞哌唑片剂药物组合物及其制备方法